Induced Lactation with a Dopamine Antagonist in Mares: Different Responses between Ovariectomized and Intact Mares

Autor: Yves Combarnous, G. Duchamp, Peter Daels, P. Nagy, Daniel Guillaume, Nadine Martinat, Pascale Chavatte-Palmer
Rok vydání: 2003
Předmět:
Zdroj: Reproduction in Domestic Animals. 38:394-400
ISSN: 0936-6768
DOI: 10.1046/j.1439-0531.2003.00454.x
Popis: The aim of this study was to compare the effects of treatment with repeated injections of sulpiride (a dopamine D2 antagonist) on prolactin secretion and induced lactation in ovariectomized and intact adult mares and to verify if this induction was possible at the beginning and at the end of the birth season. Two experiments were carried out in September [experiment (expt) 1], and in March (expt 2), in France (48� N). In expt 1, three groups of five mares were tested: intact-control, intact-treated and ovariectomized-treated mares. In expt 2, mares previously subjected to artificial photoperiod were assigned in two groups: four intact-control and five intact-treated mares. The cyclicity of intact mares was previously synchronized with PGF2a injections, then all the mares were in the follicular phase at the beginning of treatment. Sulpiride was intramuscularly injected (0.5 mg/kg of BW), twice a day. Mares were milked at 7:30, 11:45, 16:00 and 20:15 hours. Blood samples were collected every day during the treatment for progesterone, total oestrogen and prolactin assays. In the two experiments, only treated intact mares produced milk, with a large inter-animal variability. Prolactin increase after sulpiride treatment was not so great in the ovariectomized-treated mares as in the intact-treated mares. The total correlations between prolactin, progesterone, oestrogen plasma concentrations and daily milk production were significant (0.57, 0.25, 0.17 respectively). This induction of lactation can be performed during the entire birth season in intact mares, but not in ovariectomized mares, indicating that steroids are necessary for this induction in mares treated by dopamine D2 antagonist.
Databáze: OpenAIRE